These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9667672)

  • 1. Time trends in breast cancer survival: experience in a single centre, 1975-89.
    Bradburn MJ; Altman DG; Smith P; Fentiman IS; Rubens RD
    Br J Cancer; 1998 Jun; 77(11):1944-9. PubMed ID: 9667672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Subtypes and Prognostic Factors among Premenopausal and Postmenopausal Thai Women with Invasive Breast Cancer: 15 Years Follow-up Data.
    Tubtimhin S; Promthet S; Suwanrungruang K; Supaattagorn P
    Asian Pac J Cancer Prev; 2018 Nov; 19(11):3167-3174. PubMed ID: 30486605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Time Since Last Childbirth on Survival of Women with Premenopausal and Postmenopausal Breast Cancers.
    Balakrishnan N; Teo SH; Sinnadurai S; Bhoo Pathy NT; See MH; Taib NA; Yip CH; Bhoo Pathy N
    World J Surg; 2017 Nov; 41(11):2735-2745. PubMed ID: 28653143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women.
    Love RR; Van Dinh N; Quy TT; Linh ND; Tung ND; Shen TZ; Hade EM; Young GS; Jarjoura D
    J Clin Oncol; 2008 Jan; 26(2):253-7. PubMed ID: 18086800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast Tumor Prognostic Characteristics and Biennial vs Annual Mammography, Age, and Menopausal Status.
    Miglioretti DL; Zhu W; Kerlikowske K; Sprague BL; Onega T; Buist DS; Henderson LM; Smith RA;
    JAMA Oncol; 2015 Nov; 1(8):1069-77. PubMed ID: 26501844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Prognostic Analysis of Male Breast Cancer (MBC) Compared with Post-Menopausal Female Breast Cancer (FBC).
    Yu XF; Yang HJ; Yu Y; Zou DH; Miao LL
    PLoS One; 2015; 10(8):e0136670. PubMed ID: 26313461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III randomized equivalence trial of early breast cancer treatments with or without axillary clearance in post-menopausal patients results after 5 years of follow-up.
    Avril A; Le Bouëdec G; Lorimier G; Classe JM; Tunon-de-Lara C; Giard S; MacGrogan G; Debled M; Mathoulin-Pélissier S; Mauriac L;
    Eur J Surg Oncol; 2011 Jul; 37(7):563-70. PubMed ID: 21665421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
    Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group.
    J Natl Cancer Inst; 1996 Nov; 88(21):1543-9. PubMed ID: 8901852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis.
    Protani M; Coory M; Martin JH
    Breast Cancer Res Treat; 2010 Oct; 123(3):627-35. PubMed ID: 20571870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of the effect of menopausal status and molecular subtype on survivals among breast cancer patients].
    Zuo TT; Zeng HM; Zheng RS; Yang L; Li HC; Liu S; Xia CF; Chen WQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 May; 51(5):409-414. PubMed ID: 28464591
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative effects of the administration period of adjuvant chemotherapy using doxifluridine (5'-DFUR) for 1 year versus 3 years after breast cancer surgery by the Shimane Breast Cancer Study Group.
    Shimane Breast Cancer Study Group
    Anticancer Res; 2006; 26(1B):591-7. PubMed ID: 16739326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HR+/Her2- breast cancer in pre-menopausal women: The impact of younger age on clinical characteristics at diagnosis, disease management and survival.
    De Camargo Cancela M; Comber H; Sharp L
    Cancer Epidemiol; 2016 Dec; 45():162-168. PubMed ID: 27846443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour.
    Demicheli R; Bonadonna G; Hrushesky WJ; Retsky MW; Valagussa P
    Breast Cancer Res; 2004; 6(6):R689-96. PubMed ID: 15535851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer in pre-menopausal women in West Africa: analysis of temporal trends and evaluation of risk factors associated with reproductive life.
    Sighoko D; Kamaté B; Traore C; Mallé B; Coulibaly B; Karidiatou A; Diallo C; Bah E; McCormack V; Muwonge R; Bourgeois D; Gormally E; Curado MP; Bayo S; Hainaut P
    Breast; 2013 Oct; 22(5):828-35. PubMed ID: 23489760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
    Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of relapse in breast cancer: changes over time.
    Yerushalmi R; Woods R; Kennecke H; Speers C; Knowling M; Gelmon K
    Breast Cancer Res Treat; 2010 Apr; 120(3):753-9. PubMed ID: 19701704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
    Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
    Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer.
    Gordon NH; Silverman P; Lasheen W; Meinert J; Siminoff LA
    Breast Cancer Res Treat; 2007 May; 102(3):301-12. PubMed ID: 17033926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.